A liquid biopsy measuring levels of circulating tumour DNA (ctDNA) could represent the future for ovarian cancer patients. A recent study by Cancer Research UK Cambridge Institute, published in PLOS Medicine, found ctDNA results correlated with the size of ovarian cancers and were predictive of treatment response. Jean-Charles Soria, director of the Site de Recherche Intégrée sur le Cancer Socrate project at Gustave Roussy Cancer Campus, Paris, said liquid biopsies were "the most transformational thing" to impact clinical cancer trials and patient management over December 20.
A liquid biopsy measuring levels of circulating tumour DNA (ctDNA) could represent the future for ovarian cancer patients. A recent study by Cancer Research UK Cambridge Institute, published in PLOS Medicine, found ctDNA results correlated with the size of ovarian cancers and were predictive of treatment response. Jean-Charles Soria, director of the Site de Recherche Intégrée sur le Cancer Socrate project at Gustave Roussy Cancer Campus, Paris, said liquid biopsies were "the most transformational thing" to impact clinical cancer trials and patient management over the next five years.